383 related articles for article (PubMed ID: 36268012)
1. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
[TBL] [Abstract][Full Text] [Related]
2. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.
Yao S; Jianlin C; Zhuoqing Q; Yuhang L; Jiangwei H; Guoliang H; Hongmei N; Bin Z; Liangding H
Front Immunol; 2021; 12():639217. PubMed ID: 33868266
[No Abstract] [Full Text] [Related]
5. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
6. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.
Martino M; Fedele R; Moscato T; Ronco F
Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
[TBL] [Abstract][Full Text] [Related]
11. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
12. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
13. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
14. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
16. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
17. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
18. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
20. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
